2 Best Small-Cap Mental Health Tech & Psychedelic Therapeutics Stocks — May 2026
The investable small-cap mental-health-tech and psychedelic-therapeutics universe is sparse. Most psychedelics names are micro-cap or pre-revenue; we have one credible psychedelics developer in our scored universe, plus context on what's missing.
Mental-health-tech as a small-cap public-equity category is genuinely sparse. The most-cited psychedelic-therapeutics names — MindMed, Compass Pathways — are either micro-cap or trade outside our small-cap definition. The digital-therapeutics SPAC class (Pear Therapeutics, Akili) impaired heavily through 2023-2024. What remains in our scored universe is one credible psychedelics name (ATAI) and a small set of broader specialty-pharma names that screen for adjacent indications.
We scored every small-cap with mental-health, psychedelic-therapeutic, or digital-therapeutic primary exposure. The set is short. We list what's there honestly, with explicit notes on what's missing and why the public-equity universe is thin.
Why Small-Cap Mental Health Tech & Psychedelic Therapeutics Is Different
- Public small-cap psychedelics exposure is genuinely thin — most names are micro-cap, OTC-listed, or trade outside US small-cap definitions. The sub-segment hasn't matured into a clean public-equity layer.
- Digital-therapeutics SPAC class largely impaired — Pear Therapeutics, Akili, and similar PSPC-era digital-mental-health names have either delisted, restructured, or trade as micro-caps with sustained dilution.
- FDA path for psychedelics is binary and uncertain — Lykos Therapeutics' MDMA-PTSD application was rejected in 2024, prompting a broader resetting of FDA-psychedelic timelines. Subsequent applications face higher trial-design and abuse-liability bars.
- Insurance coverage is the post-FDA gating variable — even if approved, payer coverage for psychedelic-assisted therapy (with mandatory therapist oversight) is the next economic variable, currently uncertain.
Our scoring rewards balance-sheet quality and capital discipline. For pre-commercial mental-health-tech names, runway-through-clinical-readouts and dilution discipline are the primary metrics; the FDA-binary nature of the category makes position-sizing more important than stock-picking.
Top 2 Small-Cap Mental Health Tech & Psychedelic Therapeutics Stocks by Fundamental Score — May 2026
Get picks like these first.
Free weekly digest — top movers, score changes, new small-cap opportunities. No spam, unsubscribe anytime.
1. Akebia Therapeutics, Inc. (AKBA) — Score: 77.3 | Grade: SOLID
| Metric | Value | Score |
|---|---|---|
| Revenue Growth YoY | +47.5% | 76 |
| Gross Margin | 83.3% | 100 |
| Cash Runway | >36 months | 100 |
| Debt/Equity | 158.84 | 0 |
| P/S Ratio | 1.6x | 97 |
| Rule of 40 | 57.4 | 97 |
| Insider Ownership | 4.2% | 34 |
| 12m Dilution | +2.4% | 86 |
What drives the score: Akebia Therapeutics commercializes Vafseo (vadadustat), an oral HIF-PH inhibitor for anemia in dialysis patients. Not a mental-health product — included here only as small-cap drug-developer reference; scoring well due to commercial revenue ramp post-FDA approval.
Key risk: Akebia's commercial product Vafseo (vadadustat) is for anemia in dialysis patients — not a mental-health drug. Listed here only because the screen returned it; readers seeking pure mental-health exposure should screen this out. The fundamental score is high because of post-FDA-approval revenue ramp.
Market cap: $375M. Industry: Drug Manufacturers - Specialty & Generic.
2. AtaiBeckley Inc. (ATAI) — Score: 12.1 | Grade: CRITICAL
| Metric | Value | Score |
|---|---|---|
| Revenue Growth YoY | -1.9% | 0 |
| Gross Margin | N/A | 0 |
| Cash Runway | 3 months | 4 |
| Debt/Equity | 21.24 | 83 |
| P/S Ratio | 360.2x | 0 |
| Rule of 40 | -33172.7 | 0 |
| Insider Ownership | 3.7% | 29 |
| 12m Dilution | +116.3% | 0 |
What drives the score: ATAI Life Sciences (now ATAI Beckley after 2025 merger with Beckley Psytech) is a psychedelic-drug developer with multiple programs across MDMA, psilocybin analogs, and ibogaine derivatives. Lead is BPL-003 (intranasal mebufotenin) for treatment-resistant depression. Pre-commercial, dilution-funded, FDA-calendar-driven.
Key risk: Multiple-program portfolio diversifies binary risk somewhat, but each program faces FDA, trial-design, and payer-coverage uncertainty. BPL-003 (intranasal mebufotenin) for treatment-resistant depression is the lead — Phase 2b data through 2025-2026 is the major catalyst window. Dilution-funded; equity issuance through 2027 is likely until lead program reaches NDA filing.
Market cap: $1.47B. Industry: Biotechnology.
What these 2 stocks have in common
-
Only ATAI is a real fit for the theme. AKBA and VLN are screen artifacts — readers should treat this list as effectively single-name exposure. The thinness of the public-investable universe is itself the most important signal.
-
Psychedelics has a genuine clinical-validation story — multiple Phase 2 readouts for treatment-resistant depression, PTSD, and substance-use disorder are scheduled through 2026-2027. ATAI participates in this calendar through multiple programs.
-
Single-name concentration risk dominates. Investors looking to add mental-health-tech exposure at the small-cap level will face concentration; diversification typically requires going to private markets, foreign listings, or accepting non-pure-play biotech ETF exposure.
What's not on this list — and why
- MindMed (MNMD) — sub-$1B market cap typical; not currently in our scored universe. Lead program MM120 (LSD analog) for generalized anxiety in Phase 3.
- Compass Pathways (CMPS) — sub-$1B; not currently scored. Lead program COMP360 (psilocybin) for treatment-resistant depression.
- Cybin (CYBN) — Toronto-listed, US-OTC. Lead is CYB003 (psilocybin analog).
- Lykos Therapeutics — MAPS spin-out; MDMA-PTSD application rejected by FDA in 2024.
- Pear Therapeutics, Akili Interactive — digital-therapeutics SPAC casualties; both substantially impaired.
The public small-cap mental-health-tech universe is thin enough that single-name concentration is unavoidable for investors building this exposure. Most of the credible psychedelic-therapeutic candidates are either OTC-listed, micro-cap, or trade in foreign markets; the digital-therapeutic sub-segment has been substantially impaired. Investors should treat this category as exploratory rather than as a core allocation lane.
How to use this data
These scores measure financial health and capital efficiency. For mental-health-tech names specifically:
- Track FDA-meeting calendar (Type C, end-of-Phase-2) and clinical-trial readouts; binary-event-driven
- For ATAI, BPL-003 Phase 2b readout window is the dominant catalyst; portfolio-program diversity is the structural advantage
- Position-sizing should be small (1-2% of diversified portfolio per name) given binary outcomes
- Consider whether portfolio-level mental-health-tech allocation is genuinely warranted vs. broader biotech ETF exposure
SmallCapScanner scores are calculated algorithmically based on 8 fundamental factors. They measure financial health, not future performance. See /how-it-works for the full methodology.
Track these stocks and 2,200+ others on our screener. Set alerts to know when a score crosses your threshold, or compare two tickers directly on /compare.